Sequence Bio is pleased to welcome Dr. Bari Ballew to its scientific leadership team.
Dr. Ballew, a bioinformatics scientist by training, joins Sequence Bio after more than a decade at the forefront of biomedical research with the National Institutes of Health, National Cancer Institute, and drug discovery company 54gene.
As the Senior Director of Data Science & Analytics, Dr. Ballew will lead the continued build-out of Sequence Bio’s bioinformatics production team. She will also lead the development of Sequence Bio’s bioinformatics pipelines to analyze multi-dimensional data sets in support of the company’s drug target discovery and research collaborations.
For Dr. Ballew, joining Sequence Bio is a unique opportunity to help uncover novel insights about the biological basis of disease.
“The Sequence Bio team is united by working on big challenges that can have a lasting, positive impact on people around the world. For me, that means combining state-of-the-art computer science, statistics, software engineering, and computational biology methods to help uncover important relationships between billions of biological and medical data points,” said Dr. Ballew.
“I’m excited to collaborate with the people of Newfoundland and Labrador and our pharma industry partners to help accelerate the discovery of potentially life-changing medicines.”
Sequence Bio’s Chief Science Officer Dr. Roderick Scott added, “Dr. Ballew’s work at the intersection of genomics and data science gives her unique, hands-on experience integrating the latest computational and machine learning applications for data-driven drug discovery."
He continued, “Bari is exceptionally well qualified to lead the continued advancement of Sequence Bio’s bioinformatics infrastructure while upholding our focus on protecting the privacy of research participants.”
Dr. Ballew received her doctorate in biology from the University of California San Diego and completed her training as a postdoctoral fellow at the National Institutes of Health.
Sequence Bio is a commercial-stage biotechnology company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across numerous disease indications. Sequence Bio collaborates with the people of Newfoundland and Labrador, and partners with leading pharma and biotech to help accelerate the development of new medicines for global unmet medical needs.